4 Healthcare Stock Stories for Monday Wellness

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Dynavax Technologies Corporation (NASDAQ:DVAX): Closing price $2.01

On Monday, Dynavax said that it has received a Complete Response Letter from the FDA regarding its Biologic License Application for Heplisav, its  investigational adult hepatitis B vaccine. The agency specified that the indication in adults 18-70 years of age cannot be approved without further study of safety in this broad age group, and also continues to express concern that novel adjuvants could cause rare autoimmune events. However, the FDA indicated its willingness to continue talks regarding a more restricted use of Heplisav.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

dvax

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business